Stock NBIX NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
136 USD -1.28% Intraday chart for Neurocrine Biosciences, Inc. +3.02% +3.21%
Apr. 24 Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170 MT
Apr. 24 Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,899 8,955 8,080 11,482 12,946 13,678 - -
Enterprise Value (EV) 1 9,279 8,472 7,704 10,363 11,397 11,588 10,798 10,048
P/E ratio 276 x 23 x 92.6 x 76.6 x 53.3 x 28.8 x 21.3 x 16.3 x
Yield - - - - - - - -
Capitalization / Revenue 12.6 x 8.56 x 7.13 x 7.71 x 6.86 x 6.18 x 5.43 x 4.69 x
EV / Revenue 11.8 x 8.1 x 6.8 x 6.96 x 6.04 x 5.24 x 4.29 x 3.45 x
EV / EBITDA 116 x 44.2 x 58.9 x 39.2 x 42.4 x 20.7 x 12.6 x 9.79 x
EV / FCF 67.6 x 38.9 x 33 x 32.1 x 31.5 x 19.3 x 14.1 x 10.6 x
FCF Yield 1.48% 2.57% 3.03% 3.12% 3.17% 5.19% 7.1% 9.45%
Price to Book 15.6 x 7.92 x 5.86 x 6.75 x 5.83 x 5.01 x 3.95 x 2.84 x
Nbr of stocks (in thousands) 92,094 93,429 94,867 96,134 98,252 100,580 - -
Reference price 2 107.5 95.85 85.17 119.4 131.8 136.0 136.0 136.0
Announcement Date 2/4/20 2/4/21 2/11/22 2/6/23 2/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 788.1 1,046 1,134 1,489 1,887 2,213 2,520 2,915
EBITDA 1 79.74 191.6 130.7 264.1 268.7 560.6 855.1 1,026
EBIT 1 72.3 163 102.5 249 250.9 591.1 818.8 1,071
Operating Margin 9.17% 15.58% 9.04% 16.73% 13.3% 26.71% 32.49% 36.73%
Earnings before Tax (EBT) 1 46.5 106.7 101.4 213.9 332.1 636.4 864.4 1,117
Net income 1 37 407.3 89.6 154.5 249.7 489.9 665.5 875
Net margin 4.69% 38.94% 7.9% 10.38% 13.23% 22.13% 26.41% 30.02%
EPS 2 0.3900 4.160 0.9200 1.560 2.470 4.716 6.372 8.357
Free Cash Flow 1 137.3 217.6 233.1 323 361.6 601.5 766.7 949.5
FCF margin 17.42% 20.81% 20.56% 21.7% 19.16% 27.18% 30.43% 32.57%
FCF Conversion (EBITDA) 172.2% 113.57% 178.35% 122.3% 134.56% 107.28% 89.66% 92.53%
FCF Conversion (Net income) 371.1% 53.42% 260.16% 209.06% 144.8% 122.78% 115.2% 108.51%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/4/20 2/4/21 2/11/22 2/6/23 2/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 296 312 310.6 378.2 387.9 412 420.4 452.7 498.8 515.2 512 546.7 569.3 589.1 548.4
EBITDA 1 51.5 -28.9 6.8 59 91.8 107.3 -109.2 78.7 144 155.2 126.6 134.7 144.3 134.4 -
EBIT 1 44.5 -36.3 3.1 54.7 87.8 103.4 -114.2 73.6 141.2 150.3 118 143.8 158.6 159.3 116.8
Operating Margin 15.03% -11.63% 1% 14.46% 22.63% 25.1% -27.16% 16.26% 28.31% 29.17% 23.04% 26.31% 27.87% 27.04% 21.29%
Earnings before Tax (EBT) 1 30.5 -13.8 21.4 -23.3 97.9 117.9 -103.3 121.6 115.6 198.2 129.2 155.8 172 174.5 136.6
Net income 1 22.5 -7.3 13.9 -16.9 68.5 89 -76.6 95.5 83.1 147.7 101.2 122.3 131.2 133.2 104.3
Net margin 7.6% -2.34% 4.48% -4.47% 17.66% 21.6% -18.22% 21.1% 16.66% 28.67% 19.76% 22.37% 23.04% 22.61% 19.02%
EPS 2 0.2300 -0.0800 0.1400 -0.1800 0.6900 0.8800 -0.7900 0.9500 0.8200 1.440 0.9997 1.179 1.274 1.275 1.097
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/1/21 2/11/22 5/4/22 8/4/22 11/1/22 2/6/23 5/3/23 8/1/23 10/31/23 2/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 620 483 376 1,119 1,549 2,090 2,880 3,630
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 137 218 233 323 362 601 767 950
ROE (net income / shareholders' equity) 6.62% 46.2% 14.9% 22.3% 12.7% 22.3% 23.2% 23%
ROA (Net income/ Total Assets) 3.22% 26.8% 9.76% 15.5% 8.89% 18% 47% -
Assets 1 1,150 1,520 918 999.7 2,810 2,720 1,415 -
Book Value Per Share 2 6.900 12.10 14.50 17.70 22.60 27.20 34.40 48.00
Cash Flow per Share 2 1.590 2.340 2.620 3.430 3.860 4.860 8.960 9.170
Capex 1 14.7 10.9 23.4 16.5 28.3 19.8 20.5 20.4
Capex / Sales 1.87% 1.04% 2.06% 1.11% 1.5% 0.89% 0.81% 0.7%
Announcement Date 2/4/20 2/4/21 2/11/22 2/6/23 2/7/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Neurocrine Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
136 USD
Average target price
153.6 USD
Spread / Average Target
+12.97%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.86B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.71B
ARGENX SE Stock argenx SE
+1.69% 22.02B
BIONTECH SE Stock BioNTech SE
-17.37% 20.9B
GENMAB A/S Stock Genmab A/S
-9.30% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 15.52B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.04B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.71% 8.08B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. Financials Neurocrine Biosciences, Inc.